The unifying theme of the Tumor Signaling & Angiogenesis program is to build translational clinical trials based on innovative and novel research projects that focus on signaling cascades leading to uncontrolled cell growth and resistance to apoptosis.
The program goals are to identify dysregulated molecular signaling pathways that can be used as cancer-specific targets. Collectively the members of this program work cooperatively to study a variety of kinase targets involved in cancer cell proliferation and progression.
Targets identified in this program can be exploited to develop innovative approaches to cancer prevention and therapy that can be translated into clinical trials. The research into cancer cell signaling incorporates animal models in breast and colon cancer, as well as the pediatric cancer neuroblastoma, to study how specific signaling pathways are involved in the progression of cancer.
A group of scientists at the Georgia Cancer Center of Augusta University recently reported that CAR T cells can stay active longer and mediate tumor killing more effectively when STAT5, a key signaling molecule, is kept in an active form within CAR T cells.
Aggressive colorectal cancers set up an interactive network of checkpoints to keep the immune system at bay, scientists report.
In the early part of the last century, blood transfusions occurred directly from the donor to patient. Virgil Sydenstricker found a better way, and it's still in use today.
There appears to be an unhealthy synergy between mental illness and prostate cancer, and researchers are working to dissect the relationship by first assembling the largest dataset ever of veterans with either condition or both.
